BAYER AG

Explore why Bayer AG’s diverse portfolio and negative P/E ratio risk investor confidence and how strategic consolidation or risky expansion could reshape its future.

Discover how the U.S. Supreme Court’s review of Bayer’s glyphosate case is lifting the company’s stock, easing legal risks, and boosting future growth prospects.

Explore how Bayer’s 90% share‑price surge and new cost‑cut plan clash with looming glyphosate lawsuits and strategic biotech partnerships.

Discover how Bayer’s FDA approval of Hyrnuo and EU clearance of Lynkuet signal renewed growth amid litigation, reshaping investor outlook and boosting market potential.

Bayer AG reports a widening net loss for the second quarter of 2025, but sees core earnings per share increase by 30.9% and announces new initiatives to mitigate legal risks and drive growth.

Bayer AG hat trotz rechtlicher Herausforderungen in den USA seine Prognose für 2025 aufgrund der starken Nachfrage nach Medikamenten angehoben.